Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 286

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 286
---
 decrease will apply only to the holder providing such notice. Transferability Subject to applicable laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of transfer. 179 Fractional Shares No fractional shares of Common Stock will be issued upon the exercise of the Pre-Funded Warrants. Rather, the number of shares of Common Stock to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price. Trading Market There is no trading market available for the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. Fundamental Transactions If a “Fundamental Transaction” occurs while the Pre-Funded Warrants are outstanding (which includes, but is not limited to, merger transactions or a sale of substantially all of the company’s assets), then if holders of the Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction (as defined in the Pre-Funded Warrant), then the holder will be given the same choice as to the consideration it receives upon any exercise of either the Pre-Funded Warrants following such Fundamental Transaction. Right as a Stockholder Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder’s ownership of shares of our Common Stock, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, until they exercise their Pre-Funded Warrants. Offered Common Warrants The following summary of certain terms and provisions of the Offered Common Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Offered Common Warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Offered Common Warrant for a complete description of the terms and conditions of the Offered Common Warrants. We are offering up to 4,000,000 Offered Common Warrants to purchase up to an aggregate of 4,000,000 shares of our Common Stock. Each Offered Common Warrant will have an exercise price per share of $[ ] and will be immediately exercisable beginning on the effective date of stockholder approval of the